5-HT2A Agonist Compounds for Anti-Inflammatory Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory disorders, such as those targeting TNF-α signaling with biologic drugs, lack effective small molecule anti-inflammatory compounds that can mitigate aberrant inflammatory signaling without causing central nervous system side effects.
Innovation Solution
Development of 2C compounds, including formulas (I), (II), and (III), and their pharmaceutically acceptable salts and prodrugs, which act as potent anti-inflammatory agents with high affinity for the 5-HT2A receptor, reducing inflammation without significant behavioral effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If biologic drugs (monoclonal antibodies, soluble TNF-α receptor) are used to target TNF-α signaling, then anti-inflammatory efficacy is improved, but treatment complexity and cost increase
Solution Approach 1:
The patent replaces complex biologic drugs (monoclonal antibodies and soluble receptors) with small molecule compounds that act as 5-HT2A receptor agonists. This substitution maintains anti-inflammatory efficacy while simplifying the treatment approach, as small molecules generally have better pharmacokinetic properties, easier administration, and lower costs compared to biologic therapies.
Solution Approach 2:
The patent changes the therapeutic parameter from direct TNF-α pathway inhibition to 5-HT2A receptor agonism, which indirectly modulates inflammatory signaling. This parameter change allows achievement of anti-inflammatory effects through a different mechanistic pathway, avoiding the complexities associated with direct TNF-α targeting while maintaining therapeutic efficacy.
2Reliability
If higher dosages of 5-HT2A receptor agonists are administered to achieve therapeutic plasma levels, then anti-inflammatory efficacy is improved, but psychoactive side effects increase
Solution Approach 1:
The patent optimizes the dosage parameter to achieve a therapeutic window where plasma levels are sufficient for anti-inflammatory efficacy (demonstrated in models of asthma, rheumatoid arthritis, and inflammatory bowel disease) but remain below the threshold that triggers significant psychoactive effects. This precise parameter control allows separation of therapeutic and adverse effect domains.
Solution Approach 2:
The patent uses the 5-HT2A receptor as an intermediary target that, when activated at controlled levels, produces anti-inflammatory effects through downstream signaling pathways without directly activating CNS effects. The receptor acts as a mediator that translates controlled drug exposure into therapeutic outcomes while filtering out psychoactive side effects at appropriate dosing levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2C compounds provide effective anti-inflammatory treatment for conditions like asthma and rheumatoid arthritis with minimal psychoactive side effects, achieving therapeutic plasma levels below detection limits and maintaining low dosages to avoid CNS activation.
Implementation Method 1
compounds... that act as potent anti-inflammatory agents with high affinity for the 5-HT2A receptor
Data Source
AI summary
The invention features compounds and pharmaceutical compositions having anti-inflammatory properties. Also provided are methods of using the compounds or compositions of the invention for treating an inflammatory disorder in a subject in need thereof.